Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH) developed later, specifically designed to be a highly selective GHS-R1a agonist
Genazzani adds that the Danish study 'takes a snapshot of what is happening', but important clinical details, such as the lactation status of the patients, are missing
This article separates three questions that often get blurred together: FDA approval, compounding eligibility, and research-only availability
Observations relating to the impact of tirzepatide on bone are still very much in their infancy, but there are suggestions that this drug could improve bone strength and reduce fracture risk
Frequently Asked Questions (FAQ) Yes, for most patients
The liver and intestine are important in the production and removal of endogenous and exogenous lipids, respectively, and have an important impact on circulating lipid levels